All Activity

A Florida bill to significantly reduce the fee for military veterans to obtain medical marijuana registry identification cards has cleared another legislative committee. The House Health & Human Services Committee approved the measure from Reps. Susan Valdés (R) and Michelle Salzman (R) in a 22-0 vote on Tuesday. This comes after the legislation cleared two other House panels and as separate Senate legislation to reduce medical cannabis costs for veterans is also advancing. If HB 887 is enacted into law, veterans who have been honorably discharged would need to pay a $15 fee to obtain a medical cannabis card—down from the current $75 fee for most qualifying patients. The $15 charge would also apply to any replacement cards, as well as annual renewals. In order to qualify for the reduced fee, veterans would need to supply the state Department of Health (DOH) with a copy of their discharge release form, a U.S. Department of Veterans Affairs (VA) identification card or a Florida driver license “bearing the veteran designation.” The law would take effect beginning on July 1 of this year. “Medical cannabis has shown a promise in alleviating symptoms commonly experienced by our military veterans, like managing chronic pain, alleviating the effects of PTSD, improving sleep and the most important part of this is reducing the dependency on opioids,” Valdés said before the latest committee vote. “This bill will largely reduce the financial barriers that veterans face when accessing the card.” According to a bill analysis, the reform would have an “indeterminate, negative fiscal impact on DOH.” While there are currently more than 931,000 registered medical marijuana patients in Florida, the “number of veterans who hold active medical marijuana use registry identification cards is unknown,” and so “the amount of revenue reduction is unknown.” That said, the analysis states that the policy change would “have a positive fiscal impact on veterans who will experience a $60 reduction in the cost of the identification card under the bill.” Earlier this month, the Senate Health Policy Committee advanced a bill from Sen. Alexis Calatayud (R) that would also reduce the medical cannabis registration fees for veterans to $15 and enact other reforms to expand medical marijuana access. Under that proposal as amended, a doctor would be able to recommend up to five 70-day supply limits of cannabis or up to 10 35-day supply limits of smokable marijuana products. Under current law, they can only provide recommendations for a maximum of three 70-day supply limits for non-smokable cannabis and six 35-day supply limits for smokable marijuana. The bill, SB 1032, would further make it so doctors would need to evaluate patients for medical marijuana qualification every 52 weeks, rather than the current statutory requirement of evaluations every 30 weeks. Here’s an overview of other pending Florida marijuana bills: A House lawmaker is sponsoring a bill to legalize recreational marijuana that also aims to break up what he calls “monopolies” in the state’s current medical cannabis program by revising the business licensing structure. Another representative’s bill would protect the parental rights of medical cannabis patients, preventing them from losing custody of their children for using their medicine in accordance with state law. Other legislation would also allow doctors to recommend cannabis to any patient who has a condition for which they have been prescribed opioids. A senator is sponsoring a bill to legalize home cultivation of marijuana for registered medical cannabis patients in the state. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, a Florida campaign seeking to put marijuana legalization on the ballot is facing another complication as it continues to litigate the status of its 2026 signature drive. Under a new election law, the hundreds of thousands of signatures activists already collected for this year will not be carried over into the 2028 cycle. Smart & Safe Florida recently submitted an appeal to the state Supreme Court concerning the invalidation of about 71,000 signatures for its 2026 petition, for example. While the court agreed to close a separate case involving a legal review into the ballot measure from Smart & Safe Florida, it’s now been handed another case challenging the earlier mass signature invalidation. Back in December, advocates filed a lawsuit in the Leon County circuit court, claiming Secretary of State Cord Byrd (R) unlawfully directed county election officials to invalidate about 42,000 signatures from so-called “inactive” voters and roughly 29,000 signatures collected by out-of-state petitioners. That lawsuit came after another court upheld a previous decision to strike about 200,000 signatures that the state said were invalid because the petitions didn’t include the full text of the proposed initiative. The campaign contested the legal interpretation, but it declined to appeal the decision based on their confidence they’d collected enough signatures to make up the difference. Smart & Safe Florida has generally disputed the secretary of state’s signature count, asserting the campaign submitted over 1.4 million petitions—hundreds of thousands more than the 880,062 valid signatures required to go before voters. Ahead of the signature turn-in, Florida’s attorney general and several business and anti-marijuana groups urged the state Supreme Court to block the cannabis initiative, calling it “fatally flawed” and unconstitutional. The Florida Chamber of Commerce, Florida Legal Foundation and Judge Frank Shepherd filed a separate joint brief stating that the parties remain “especially vigilant about the abuse of the citizen initiative process by out-of-state interests that think of Florida as just another market and the citizen initiative process as just another means of exploiting that market.” The Florida Chamber of Commerce has consistently opposed attempts to move forward with adult-use legalization, even as its own polling has shown majority support for the reform. The campaign fought several legal battles this cycle to ensure that its initiative is able to qualify for ballot placement. Last month, the state attorney general’s office opened dozens of criminal investigations and submitted subpoenas requesting records from Smart & Safe Florida and its contractors and subcontractors over alleged fraud related to the petitioning effort. Activists said in November that they’d collected more than one million signatures to put the cannabis measure on the ballot, but it’s also challenged officials at the state Supreme Court level over delays the certification process, arguing that the review of the ballot content and summary should have moving forward months ago when it reached an initial signature threshold. The state then agreed to move forward with the processing. The governor campaigned heavily against an earlier version of the legalization proposal, which received a majority of voters in 2024 but not enough to meet the 60 percent threshold required to pass a constitutional amendment. Former Attorney General Ashley Moody (R) unsuccessfully contested the prior initiative in the courts. Last March, meanwhile, two Democratic members of Congress representing Florida asked the federal government to investigate what they described as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to DeSantis. The money was used to fight against a citizen ballot initiative, vehemently opposed by the governor, that would have legalized marijuana for adults. The lawmakers’ letter followed allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing Amendment 3. The governor said last February that the newest marijuana legalization measure is in “big time trouble” with the state Supreme Court, predicting it would be blocked from going before voters this year. The latest initiative was filed with the secretary of state’s office just months after the initial version failed during the November 2024 election—despite an endorsement from President Donald Trump. Smart & Safe Florida expressed optimism that the revised version would succeed in 2026. The campaign—which in the last election cycle received tens of millions of dollars from cannabis industry stakeholders, principally the multi-state operator Trulieve—incorporated certain changes into the new version that seem responsive to criticism opponents raised during the 2024 push. For example, it now specifically states that the “smoking and vaping of marijuana in any public place is prohibited.”Another section asserts that the legislature would need to approve rules dealing with the “regulation of the time, place, and manner of the public consumption of marijuana.” In 2023, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released last February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. Photo courtesy of Max Jackson. The post Florida Lawmakers Vote To Slash Medical Marijuana Fees For Military Veterans appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Virginia lawmakers have advanced a bill to legalize marijuana sales along another step in the bicameral legislative process, with a House committee approving a substitute version of a Senate-passed reform measure. The House General Laws Committee on Tuesday took up the legislation from Sen. Lashrecse Aird (D) and replaced its contents with the text of a House-passed version that’s being sponsored by the panel chair, Del. Paul Krizek (D), with some additional changes. The bill as revised passed 16-4, sending it to the Appropriations Committee for further consideration and setting the stage for a bicameral conference committee to hammer out differences between the chambers’ version following additional steps in the legislative process. “They’re still not going to be exact, but we’re working towards that,” Krizek said at the hearing. “We’re getting really close.” While the revised bill as approved in committee is nearly identical to the House version Krizek is sponsoring, the panel adopted an additional series of amendments before voting it out favorably. The proposal now stipulates that microbusiness licensees can cultivate, process or conduct retail sales at up to two locations instead of one, so long as they’re located within 10 miles of each other and operate under common ownership and control. Members also amended the legislation to clarify that current medical cannabis businesses would only be able to cultivate cannabis indoors, including in secure greenhouses with a total canopy cap of 70,000 square feet. The amendment also makes it so they could not have any additional marijuana licenses beyond their medical permits with “dual-use privileges.” Finally, the measure’s conversion fee structure was revised in a way that lets current medical marijuana businesses pay the $5 million for the privilege to serve the adult-use market in three installments: $2 million the first year, $2 million the second year and $1 million the third year. Virginia lawmakers took action on multiple marijuana bills on a key deadline last week—advancing proposals to legalize cannabis sales, provide a pathway to resentencing for prior marijuana convictions and allow medical cannabis access in hospitals for seriously ill patients. While both House and Senate marijuana sales proposals are aimed at giving adults a legal means of buying cannabis, the possession and home cultivation of which was legalized in the state in 2021, there are several substantive differences that will need to be resolved before the reform potentially goes to the governor’s desk. The House committee passage of the Senate legislation with the substitute language was another step toward those negotiations. The differences between each chamber’s original versions include the start date for legal sales, cannabis tax rates and conversion fees for current medical marijuana businesses to participate in the recreational market and the form of the regulatory body that will oversee the industry, among other issues. With respect to the Senate bill as introduced, members recently clashed in committee about amendments to the body’s version that would have added new penalties for illegal cannabis activity. The amendments at issue from the Courts of Justice Committee included penalties for consumers who buy from unlicensed sources, the recriminalization of cannabis possession by people under 21 and making sales a class 1 misdemeanor for a first offense and a crime punishable by mandatory jail time for a second offense. As revised, the bill would have also raised the penalty for unlicensed cultivation to a felony punishable by up to five years in jail and made it a felony to transport with intent to distribute cannabis across state lines. But the Finance and Appropriations Committee reversed the amendments earlier this month amid pressure from a coalition of advocacy groups that sent a letter to senators saying they undermined the “intent” of the legislation and the “will of the people” by adding criminal penalties for certain cannabis-related activity. Despite the outstanding differences, both chambers’ commercial sales bills have largely aligned with recommendations released in December by the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market. Meanwhile, certain GOP members have found themselves ideologically aligned with their Democratic colleagues throughout this legislative process, breaking with the majority of their caucus in support of creating a regulated marketplace for adults to purchase cannabis. Since legalizing cannabis possession and home cultivation in 2021, Virginia lawmakers have worked to establish a commercial marijuana market—only to have those efforts consistently stalled under former Gov. Glenn Youngkin (R), who twice vetoed measures to enact it that were sent to his desk by the legislature. Here are the key details of the Virginia marijuana sales legalization legislation, SB 542 and HB 642, prior to the House committee adoption of the substitute on Tuesday: Adults would be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. The House bill sets the state date for legal sales as November 1, 2026, while the Senate measure would allow them to begin on January 1, 2027. The Senate bill would set an excise tax on cannabis products of 12.875 percent, in addition to a 1.125 percent state sales tax and a mandatory 3 percent local tax. The House measure would apply an excise tax of 6 percent as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set a local tax of up to 3.5 percent. Under the House bill, the Virginia Cannabis Control Authority would oversee licensing and regulation of the new industry, while the Senate legislation tasks that to a new combined Alcoholic Beverage and Cannabis Control Authority. The House bill calls for revenue to be distributed to a new Cannabis Equity Reinvestment Fund (60 percent), early childhood education (10 percent), the Department of Behavioral & Developmental Health Services (25 percent) and public health initiatives (5 percent). The Senate proposal, meanwhile, would put 30 percent toward the equity reinvestment fund, 40 percent for early childhood eduction, 25 percent to the behavioral and developmental health services department and 5 percent to public health initiatives. Local governments could not opt out of allowing marijuana businesses to operate in their area. Delivery services would be allowed. Serving sizes would be capped at 10 milligrams THC, with no more than 100 mg THC per package. Existing medical cannabis operators could enter the adult-use market if they pay a licensing conversion fee that is set at $15 million in the Senate bill and $10 million in the House measure. Cannabis businesses would have to establish labor peace agreements with workers. A legislative commission would be directed to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations. It would also investigate the possibility of the Virginia Alcoholic Beverage Control Authority becoming involved in marijuana regulations and enforcement. Gov. Abigail Spanberger (D) supports legalizing adult-use marijuana sales. Meanwhile, House and Senate lawmakers also advanced separate legislation to provide resentencing relief for people with prior marijuana convictions. The legislation would create a process by which people who are incarcerated or on community supervision for certain felony offenses involving the possession, manufacture, selling or distribution of marijuana could receive an automatic hearing to consider modification of their sentences. The measure applies to people whose convictions or adjudications are for conduct that occurred prior to July 1, 2021, when a state law legalizing personal possession and home cultivation of marijuana went into effect. Also on Tuesday, the House passed a bill to enact what’s known as “Ryan’s law,” a policy change providing that patients with terminal illnesses who are registered cannabis patients can access medical marijuana at health facilities such as hospitals. It would require healthcare facilities to establish policies “to address circumstances under which an eligible patient would be permitted to use medical cannabis.” Under the House legislation, healthcare facilities could suspend medical cannabis allowances if a federal agency such as the Department of Justice or Centers for Medicare and Medicaid Services takes enforcement action on the issue or issues a rule or notification expressly prohibiting use of medical cannabis in health facilities. The Senate passed differing legislation concerning the use of medical cannabis in health care facilities earlier this month. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, the Virginia House this month approved a bill to protect the rights of parents who use marijuana in compliance with state law. Under the proposal from Del. Nadarius Clark (D), possession of use of cannabis by a parent or guardian on its own “shall not serve as a basis to deem a child abused or neglected unless other facts establish that such possession or consumption causes or creates a risk of physical or mental injury to the child.” “A person’s legal possession or consumption of substances authorized under [the state’s marijuana law] alone shall not serve as a basis to restrict custody or visitation unless other facts establish that such possession or consumption is not in the best interest of the child,” the text of the bill, HB 942, states. Separately, the Virginia Department of Labor and Industry recently published a new outlining workplace protections for cannabis consumers. The post Virginia House Lawmakers Amend Senate-Passed Marijuana Sales Bill, Setting Stage For Bicameral Negotiations appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The sponsor of the bill to eliminate the cannabis panel said it has become an unnecessary layer of bureaucracy. By Joshua Haiar, South Dakota Searchlight The controversial committee that oversees South Dakota’s medical marijuana program could come to an end. A bill sponsored by Rep. Tim Goodwin, R-Rapid City, that passed the House 41-26 on Monday would repeal the sections of state law that established the Medical Marijuana Oversight Committee. The bill goes to a Senate panel next. The medical marijuana program itself would continue, under the regulation of the state Department of Health. Current law requires the Legislature’s Executive Board to appoint an 11-member committee made up of two senators, two representatives,and seven non-legislative stakeholders from an array of backgrounds, including medicine, law enforcement, counseling and at least one patient. The panel must meet at least twice a year and make recommendations to the Legislature and the Department of Health. Goodwin said the committee made sense when the state was setting up the program after voters approved it in 2020, but he said the committee has since become an unnecessary layer of bureaucracy. He said the Department of Health and the Legislature are equipped to manage the program going forward. The legislation comes amid friction between the oversight committee and the medical marijuana industry. In November, the committee approved 11 motions, primarily calling for tighter regulations, without publishing them in advance or taking public comment on each motion. The state has 18,168 medical marijuana patient cardholders. This story was first published by South Dakota Searchlight. The post South Dakota Lawmakers Vote To Eliminate Medical Marijuana Oversight Committee appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Oregon House of Representatives has approved a bill that would allow patients with debilitating medical conditions to access medical marijuana in certain health facilities such as hospices. The legislation from Rep. Farrah Chaichi (D) cleared the chamber in a 39-3 vote on Friday, sending it to the Senate for consideration. That chamber’s Health Care Committee is scheduled to take up the proposal on Wednesday. HB 4142 would require hospice, palliative and home care organizations, as well as residential facilities, to develop rules permitting registered patients with debilitating conditions to use medical cannabis. The reform is similar to—albeit somewhat more limited than—multiple “Ryan’s law” measures that have advanced in state legislatures across the country. Ryan’s law, which is named after a young cannabis patient in California who passed away, generally refers to a policy broadly permitting medical marijuana use in health facilities such as hospitals. The Oregon bill wouldn’t extend to hospitals, but it would build upon the state’s medical cannabis program in a way that advocates say would meaningfully improve quality of life for seriously ill patients. Under the proposal, the Oregon State Board of Nursing would further be prohibited “from disciplining a nurse who discusses the medical use of marijuana with a patient,” according to a legislative summary. It would additionally make it so eligible health facilities could act as medical marijuana caregivers if authorized by regulators. The legislation “exempts residential facilities that provide a patient with medical marijuana from criminal laws related to the possession, delivery, or manufacture of marijuana” and “allows a conditionally designated residential facility to develop a written policy and train staff before the operative date,” the summary says. If enacted into law, the measure would become operative on January 1, 2027. “This bill is an important tool to facilitate cannabis use as an alternative or addition to opioid use in end-of-life care,” Chaichi said on the floor ahead of the vote. “While sometimes necessary, opioids are often overly sedative, preventing quality family time interactions in a person’s final days.” “As someone who lost my mother while she was intubated, I know how meaningful it is for patients to be present and in the moment for their last days and weeks with their loved ones,” she said. “This is a quality of life and quality of care issue. The bill’s goal is to ensure patients who desire this important and valid medical treatment have access to it.” Dena Swift, owner of Crossroads End of Life Doula Services, said in written testimony to the Senate committee ahead of its scheduled hearing that “cannabis has shown potential benefits in end-of-life care, particularly for individuals facing terminal illnesses.” “It can help alleviate symptoms such as chronic pain, nausea, anxiety, and insomnia, which are common during this stage,” she said. “Additionally, cannabis may enhance the effectiveness of traditional medications, like opioids, by reducing the required dosage and minimizing side effects. This can contribute to improved comfort and quality of life for patients in their final days.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Lawmakers in multiple states are advancing similar bills meant to provide patients with access to medical marijuana in health care facilities, with legislators across the U.S. making the case this week for a policy change they say is necessary to ensure patients have a full range of treatment options at their disposal. Last week alone, Ryan’s law proposals saw action in at least four states: Colorado, Hawaii, Virginia and Washington State. Photo courtesy of Chris Wallis // Side Pocket Images. The post Oregon House Passes Bill To Allow Medical Marijuana Access For Patients In Hospice Care appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A GOP congressman is seeking to amend a large-scale agriculture bill to delay the federal recriminalization of hemp THC products for one year as industry stakeholders work to identify a long-term solution to the pending recriminalization—and a key House committee is expected to consider the proposal next week. The hemp sector has been sounding the alarm about the cannabinoid ban that was included in broader spending legislation President Donald Trump signed into law last year. They argue that the redefinition of what constitutes federally legal hemp—which is currently set to take effect in November— would effectively upend the market that’s emerged since the crop was legalized under the 2018 Farm Bill during the president’s first term. Now Rep. Jim Baird (R-IN) is looking to get out in front of that ban with an amendment filed for the 2026 Farm Bill. The House Agriculture Committee was initially scheduled to take up the measure on Monday, but that hearing has been delayed until next week due to weather-related complications. Here’s the summary of the Baird amendment: “This amendment would delay the redefining of hemp by 1 year in section 781 of the Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act of 2026.” Delaying the THC ban by a year would serve as a temporary bridge for the industry as it works to convince Congress to regulate—rather than recriminalize—hemp products, and it’s a shorter delay than Baird is working to secure through separate standalone legislation he filed this session that would put a pause on the policy change for two years to give stakeholders more time to navigate the issue. “There is a growing, urgent desire to make sure that farmers are going to have some certainty about whether to plant their crops this spring—and they can’t right now because, if nothing changes, the ban will go into effect in November,” Jonathan Miller, general counsel of the U.S. Hemp Roundtable, told Marijuana Moment on Monday. “And at the same time, we’re starting to see support building for a regulatory approach.” “There are a ton of negotiations going on, including negotiations with the White House, and there is a general consensus that something needs to be done,” he said. “I know not everybody agrees on the specifics of a fix, but there is general consensus that that this needs to be fixed and that there needs to be more time to allow for that fix.” Since 2018, cannabis products have been considered legal hemp if they contain less than 0.3 percent delta-9 THC on a dry weight basis. The provisions set to take effect later this year specify that, within one year of enactment, the weight will apply to total THC—including delta-8 and other isomers. It will also include “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services).” The new definition of legal hemp will additionally ban “any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or not capable of being naturally produced by it. Legal hemp products will be limited to a total of 0.4 milligrams per container of total THC or any other cannabinoids with similar effects. Within 90 days of the bill’s enactment, the Food and Drug Administration (FDA) and other agencies were supposed to publish list of “all cannabinoids known to FDA to be capable of being naturally produced by a Cannabis sativa L. plant, as reflected in peer reviewed literature,” “all tetrahydrocannabinol class cannabinoids known to the agency to be naturally occurring in the plant” and “all other known cannabinoids with similar effects to, or marketed to have similar effects to, tetrahyrocannabinol class cannabinoids.” However, FDA appears to have missed that deadline. A spokesperson told Marijuana Moment earlier this month that the lists would be posted in the Federal Register when they’re available. Lawmakers from across the aisle have been raising concerns about the potential consequences of the hemp redefinition, which would eradicate most consumable cannabinoid products that have become commonplace in states across the U.S., including those where marijuana hasn’t been legalized. Rep. James Comer (R-KY) and Kentucky Agriculture Commissioner Jonathan Shell are among the critics of the ban, and they sent a letter to Sen. Mitch McConnell (R-KY) last week imploring him to use his influence to avert the recriminalization, at least on a temporary basis, by supporting the proposed implementation delay. While McConnell championed hemp legalization under the 2018 Farm Bill, however, the former Senate majority leader has supported unraveling the hemp THC market that he’s described as an unintended consequences of the broader agriculture legislation. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, last month, major alcohol retailers came together to encourage Congress to delay the enactment of the law Trump signed that will federally recriminalize hemp-derived THC beverages and other products. The coalition says it wants to apply the same regulatory structure that governs beverage alcohol producers, distributors and merchants to hemp drinks “to ensure safe, transparent access.” Other alcohol industry groups such as Wine & Spirits Wholesalers of America have also backed regulating hemp products instead of prohibiting them. The post Key Congressional Committee Could Vote On Delaying Federal Hemp THC Ban Next Week appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Support for legalizing the use of psychedelics might relatively low today, according to a new survey from the RAND Corporation, but public opinion on the issue seems be closely following in the footsteps of the marijuana reform movement before the first states started enacting cannabis legalization. As more states and localities, as well as Congress, see momentum around psychedelics reform, the poll that was released on Tuesday shows that Americans are currently feeling relatively tepid about the prospect of expanding access to hallucinogenic substances. However, there’s reason to believe that could change dramatically in the years to come if cannabis-related polling is any indication. For now, just 23 percent of respondents said that psilocybin mushrooms should be legal, and even fewer (around 10 percent) expressed support for legalizing LSD or MDMA. By contrast, RAND’s data reaffirms that there’s strong majority support (65 percent) for the legalization of marijuana. Of course, it’s relatively early in the push for psychedelics reform. And a look at the public opinion trajectory for cannabis may offer a window into what’s to come. “Support for the legal use of psilocybin mushrooms is similar to what it was for cannabis in the mid-1990s—just before state medical cannabis laws started to be implemented,” the poll found, with authors adding that it’s “unclear whether psilocybin will follow a similar trajectory in terms of public opinion or policy changes.” The think tank said that are “some reasons” that could explain the trend. For example, one could also better understand the current sentiment toward psychedelics in the context of how opinions shifted around same-sex marriage. “From 1995 to 2016, public support for legalizing marijuana rose in tandem with support for same-sex marriage,” it said. “This suggests that both shifts may have been driven by broader, time-specific increases in socially liberal attitudes rather than by issue-specific factors. If that period reflected a unique generational or cultural moment, the same underlying forces might not be present in the near term.” Support for legalizing psilocybin was high (62 percent) among those who’ve used the psychedelic. Similarly, 80 percent of adults who’ve used marijuana are in favor of the plant’s legalization. Only 42 percent of those who support the legal use of psilocybin say that adults should be able to use them for any reason, while 56 percent say it should be allowed for medical purposes. Overall, just over 10 percent of respondents said psilocybin should be allowed for any use; for LSD and MDMA, that percentage drops to under 10 percent, and support for the medical use of the three psychedelics is all under 30 percent for the general public. “When respondents were asked about reasons for allowing legal use, addressing a mental or physical health condition is the most endorsed reason for psilocybin, LSD, and MDMA,” the survey found. “When respondents were asked where adults should get psilocybin mushrooms if they were legal, using them at a medical facility under supervision is the most endorsed option (49 percent). About 28 percent endorse getting psilocybin mushrooms from a dispensary, and 23 percent endorse allowing adults to grow or forage for personal use.” “Among the three psychedelic substances that our policy questions focused on (psilocybin mushrooms, LSD, and MDMA), psilocybin mushrooms had the most support among U.S. adults when asked a simple question about its legality and when asked more-detailed questions about reasons for use and potential sources of supply,” RAND said. “These findings may not be surprising considering that psilocybin mushrooms are the most-used psychedelic substance among U.S. adults.” “Among the three psychedelic substances that our policy questions focused on, psilocybin mushrooms are also the most commonly included psychedelic substances in state and local policy initiatives in the United States,” it said. The survey, conducted by the National Opinion Research Center (NORC) at the University of Chicago, involved interviews with 10,122 American adults from September 9, 2025 to October 1, 2025. The margin of error was +/-1.33 percentage points. “To the best of our knowledge, the 2025 RPS is the first probability-based and nationally representative survey to examine policy preferences for individual psychedelic substances rather than asking about the entire class of psychedelics,” RAND said. Meanwhile, RAND researchers separately released data last month showing that nearly 10 million American adults microdosed psychedelic substances such as psilocybin, LSD or MDMA in 2025. The results of the RAND Corporation survey indicated that microdosing—which involves ingesting a small amount of a drug to improve mood and well-being without experiencing hallucinations or a full-scale trip—is a popular practice in the U.S., despite the recent polling that shows limited support for broader legalization of psychedelics. The latest results are a follow-up to an earlier report RAND issued in 2024 that made the case that “now is the time” for federal policymakers to decide how to regulate psilocybin and other psychedelic substances. Despite federal prohibition, that report noted, since 2019 more than two dozen localities have deprioritized the enforcement of laws around psychedelics, “generally making it a low or the lowest priority for law enforcement officials.” Voters in Oregon have also legalized supervised use of psilocybin, while Colorado voters legalized not only facilitated psilocybin use but also personal possession and production of psilocybin, DMT, non-peyote mescaline and other psychedelics. “Now is the time for federal policymakers to decide what they want these supply models to look like and to start taking action,” the RAND report says. “Or, if they prefer a patchwork of state policies—possibly including those that allow for commercial supply and promotion—they can do nothing and just watch the industry grow.” “If that happens,” it adds, “it can be difficult to make major changes to supply or regulations, but that will depend on the size and political power of the industry that has taken root.” The RAND Corporation, which is funded in large part by the U.S. government, is a nonprofit think tank and public consulting firm that’s helped advise policymakers on various issues. In 2021, for example, it released a government-funded report concluding that past cannabis use had relatively little impact on U.S. Army recruits’ overall performance. Researchers at RAND also contributed to a 2018 report that found that past-month marijuana consumption decreased by a small but statistically significant amount among 8th and 10th grade students in Washington State following legalization there. Photo elements courtesy of carlosemmaskype and Apollo. The post Americans’ Support For Legalizing Psychedelics Is Where Marijuana Was In The 1990s Before State Reforms, Poll Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

It's a superior strategies notably to help you the a newcomer to blogosphere, summary and even legitimate information… Bless you designed for writing this town. Required browse guide. abonnement iptv hd

La pérennité d'un espace de loisir numérique dépend de sa capacité à protéger son audience, une philosophie d'encadrement au cœur du fonctionnement de https://winzter.vip/. Conscient des responsabilités éthiques liées à son secteur, l'opérateur a intégré des outils de modération directement dans l'interface de gestion des comptes. Ces fonctionnalités permettent à chaque utilisateur de définir en toute autonomie ses propres limites d'activité, assurant une pratique saine et maîtrisée du divertissement dans un cadre protégé. Cette approche préventive est soutenue par des algorithmes de veille interne capables d'identifier les variations soudaines de comportement sur la plateforme. Le système peut déclencher des notifications informatives pour inciter à la modération, prouvant que l'établissement privilégie la protection du public sur le long terme. Cette bienveillance opérationnelle est complétée par une accessibilité simplifiée aux procédures de pause temporaire, offrant un filet de sécurité fiable pour maintenir le plaisir de l'exploration sans jamais basculer dans l'excès.

“America does not have a marijuana crisis. It has a knowledge deficit, a training deficit and a regulatory deficit layered on top of decades of stigma.” By Jill Simonian and Codi Peterson, Pharmacists’ Cannabis Coalition of California The New York Times editorial board recently warned that America now faces a “marijuana problem,” suggesting that legalization has produced a public health crisis. That framing is misleading, and in contrast to that very same board’s previous recommendation. The piece’s headline collapses a complicated medical and regulatory landscape into an all-too-familiar story about excess and loss of control—and in doing so risks reversing years of evidence-based progress in drug policy, clinical practice, social equity and patient education. Contrary to the impression created by the Times editorial, federal cannabis policy has not meaningfully loosened. Cannabis remains classified as a Schedule I substance under the Controlled Substances Act, where it has been for over 50 years. In 2024, federal health agencies formally acknowledged that cannabis has accepted medical use and recommended reclassification to Schedule III. That process stalled before completion and now sits with the Department of Justice, where no action has occurred. Research remains tightly restricted, prescribing remains impossible and clinical integration remains highly fragmented. Describing this regulatory environment as permissive is simply inaccurate, regardless of state-by-state regulations. Much of the argument about rising harm rests on claims that cannabis use has skyrocketed, based on comparisons between surveys conducted in 2000 and those conducted in 2023. These comparisons ignore a basic methodological reality. In 2000, cannabis was illegal in nearly every jurisdiction and carried substantial legal and social risk. Under those conditions, underreporting was inevitable. Today, cannabis is legal in most states and social stigma has declined. People disclose use more honestly. Increased reporting reflects increased transparency, not necessarily increased consumption. Any serious analysis of population data must account for this social acceptance drift. Cannabis is not without risk, and no responsible clinician should pretend otherwise. It can cause sedation, impaired coordination, anxiety and cognitive effects. In some individuals, particularly with heavy or prolonged use, it can precipitate acute psychosis. Cannabinoid hyperemesis syndrome is real and increasingly recognized in emergency departments. Cannabis can also interact with other medications through shared metabolic pathways and additive sedative effects. These risks underscore the need for proper screening, counseling and monitoring within the healthcare system. They do not justify framing cannabis as uniquely dangerous. Many routinely prescribed medications carry comparable or greater risks, including opioids, benzodiazepines and certain antidepressants. Unlike opioids, cannabis does not cause respiratory depression and cannot produce a fatal overdose—a distinction that matters in clinical risk assessment. Moreover, multiple studies and clinical observations suggest that some patients reduce or discontinue opioid use after initiating medical cannabis therapy. Proposals to cap THC potency are similarly disconnected from real-world behavior. Clinical and behavioral research indicates that most users self-titrate, adjusting dose based on strength, tolerance and desired effect. Higher-potency products typically lead to smaller consumption volumes rather than greater intoxication. Imposing arbitrary percentage limits substitutes symbolic regulation for evidence-based policy and ignores basic pharmacological principles. Calls for increased federal involvement are more reasonable but still incomplete. Addressing false or exaggerated medical claims is necessary, and misleading marketing harms patients. The deeper problem, however, is that cannabis remains largely segregated from mainstream healthcare. Most clinicians receive little formal education on cannabinoid pharmacology. Medication reconciliation rarely includes detailed cannabis use. Drug interaction databases remain incomplete. Clinical guidelines remain fragmented. As a result, many patients rely on dispensary staff for guidance. These individuals may be knowledgeable and well-intentioned, but they are not trained healthcare professionals, do not have access to full medical records and cannot adequately assess comorbidities or polypharmacy. That responsibility belongs in clinics and pharmacies, which have been reluctant to engage in good faith efforts due to federal illegality. The Times editorial also largely ignores the documented medical benefits of cannabis. Federal agencies already recognize accepted medical use for nausea, appetite loss and chronic pain. Clinical trials and decades of international experience support applications in palliative care, neurology, inflammatory conditions and symptom management in chronic illness. These findings are not speculative. They are part of the global medical literature. What remains underdeveloped is systematic education. Cannabis is rarely taught in medical or pharmacy curricula. Continuing education is inconsistent. Professional guidelines lag behind practice. In this vacuum, patients turn to internet forums, marketing materials and informal advice. That is not how modern medicine manages complex therapies. America does not have a marijuana crisis. It has a knowledge deficit, a training deficit and a regulatory deficit layered on top of decades of stigma. We have normalized widespread use without building the clinical and institutional structures needed to manage it responsibly, and then express surprise when problems emerge. This is not a failure of legalization. It is a failure of integration. We already know how to regulate powerful and potentially risky substances. We do it every day with anticoagulants, biologics, chemotherapeutics and opioids through education, monitoring, surveillance and professional accountability. Cannabis has been excluded from this system for political reasons, not scientific ones. Raising taxes, banning products and recycling alarmist narratives will not correct that. Building a coherent medical and regulatory framework will. If policymakers are serious about public health, they should stop treating cannabis as a moral or cultural problem and start treating it as what it is: a widely used therapeutic and psychoactive agent that deserves the same rigor, oversight and honesty as every other drug in modern medicine. Fear is easy. Evidence is harder. Only one produces durable policy. Dr. Jill Simonian is an affiliate faculty professor at University of California San Diego and University of California Irvine Schools of Pharmacy, teaching Cannabis Pharmacology & Therapeutics. She is president of the Pharmacists’ Cannabis Coalition of California (PCCC), a non-profit organization committed to bringing evidence-based cannabis education to healthcare professionals. Dr. Codi Peterson is a pediatric emergency pharmacist, educator and cannabis science expert. He is chief science officer at The Cannigma, a founding member of PCCC and a board member of Americans for Safe Access. The post America Doesn’t Have A ‘Marijuana Problem,’ As NYT Claims—It Has a Cannabis Education Problem (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

As Virginia lawmakers push ahead with an effort to legalize marijuana sales in the commonwealth, certain GOP members are finding themselves ideologically aligned with their Democratic colleagues, breaking with the majority of their caucus in support of creating a regulated marketplace for adults to purchase cannabis. In a series of recent interviews, Republican legislators explained their votes last week to pass a House bill that would allow commercial cannabis sales at licensed retailers. The Senate similarly approved marijuana sales legislation last week, though it differs from the House version in ways that will ultimately need to be resolved before reaching the governor’s desk. Del. Otto Wachsmann (R) told WVTF’s Radio IQ last week that he “went back and forth” on the proposed reform “a number of times” before making the choice to join the majority in support of HB 642 from Del. Paul Krizek (D). “By putting guardrails on it and having a legal, legitimate market instead of the black market, we can better control underaged sales, hopefully eliminate those, as well as verify that that product being used is pure product that’s not adulterated,” Wachsmann said. Asked about his vote in favor of the sales bill, Del. Wren Williams (R) said that while “you can’t get everything you’d like,” and “there are details about the bill that I don’t like,” he does want Virginia “to get that regulated market into place instead of having to just continue to fight the black market that we are seeing across the commonwealth.” Del. Will Morefield (R), for his part, declined to comment directly on his vote, saying he’d wait to review whatever version emerges from the Senate now that it’s been passed off to that chamber. But he said of the Virginia GOP caucus that members voting against the proposal are likely responsive to constituent feedback in their districts. “Some people have a moral stance against it just like some people don’t like any kind of drinking or anything,” he said. Virginia’s legislature took action on multiple marijuana bills on a key deadline last week—advancing proposals to legalize cannabis sales, provide a pathway to resentencing for prior marijuana convictions and allow medical cannabis access in hospitals for seriously ill patients. While both House and Senate marijuana sales measures are aimed at giving adults a legal means of buying cannabis, the possession and home cultivation of which was legalized in the state in 2021, there are several substantive differences that will need to be resolved before the reform potentially goes to the governor’s desk. Those differences between the chambers’s versions include the start date for legal sales, cannabis tax rates and conversion fees for current medical marijuana businesses to participate in the recreational market and the form of the regulatory body that will oversee the industry, among other issues. With respect to the Senate bill, members recently clashed in committee about amendments to the body’s version that would have added new penalties for illegal cannabis activity. The amendments at issue from the Courts of Justice Committee included penalties for consumers who buy from unlicensed sources, the recriminalization of cannabis possession by people under 21 and making sales a class 1 misdemeanor for a first offense and a crime punishable by mandatory jail time for a second offense. As revised, the bill would have also raised the penalty for unlicensed cultivation to a felony punishable by up to five years in jail and made it a felony to transport with intent to distribute cannabis across state lines. But the Finance and Appropriations Committee reversed the amendments earlier this month amid pressure from a coalition of advocacy groups that sent a letter to senators saying they undermined the “intent” of the legislation and the “will of the people” by adding criminal penalties for certain cannabis-related activity. Despite some key differences, both chambers’ commercial sales bills largely align with recommendations released in December by the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market. Since legalizing cannabis possession and home cultivation in 2021, Virginia lawmakers have worked to establish a commercial marijuana market—only to have those efforts consistently stalled under former Gov. Glenn Youngkin (R), who twice vetoed measures to enact it that were sent to his desk by the legislature. Here are the key details of the Virginia marijuana sales legalization legislation, SB 542 and HB 642: Adults would be able to purchase up to 2.5 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. The House bill sets the state date for legal sales as November 1, 2026, while the Senate measure would allow them to begin on January 1, 2027. The Senate bill would set an excise tax on cannabis products of 12.875 percent, in addition to a 1.125 percent state sales tax and a mandatory 3 percent local tax. The House measure would apply an excise tax of 6 percent as well as a 5.3 percent retail sales and use tax, while allowing municipalities to set a local tax of up to 3.5 percent. Under the House bill, the Virginia Cannabis Control Authority would oversee licensing and regulation of the new industry, while the Senate legislation tasks that to a new combined Alcoholic Beverage and Cannabis Control Authority. The House bill calls for revenue to be distributed to a new Cannabis Equity Reinvestment Fund (60 percent), early childhood education (10 percent), the Department of Behavioral & Developmental Health Services (25 percent) and public health initiatives (5 percent). The Senate proposal, meanwhile, would put 30 percent toward the equity reinvestment fund, 40 percent for early childhood eduction, 25 percent to the behavioral and developmental health services department and 5 percent to public health initiatives. Local governments could not opt out of allowing marijuana businesses to operate in their area. Delivery services would be allowed. Serving sizes would be capped at 10 milligrams THC, with no more than 100 mg THC per package. Existing medical cannabis operators could enter the adult-use market if they pay a licensing conversion fee that is set at $15 million in the Senate bill and $10 million in the House measure. Cannabis businesses would have to establish labor peace agreements with workers. A legislative commission would be directed to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations. It would also investigate the possibility of the Virginia Alcoholic Beverage Control Authority becoming involved in marijuana regulations and enforcement. Newly sworn-in Gov. Abigail Spanberger (D) supports legalizing adult-use marijuana sales. Meanwhile, House and Senate lawmakers also advanced separate legislation to provide resentencing relief for people with prior marijuana convictions. The legislation would create a process by which people who are incarcerated or on community supervision for certain felony offenses involving the possession, manufacture, selling or distribution of marijuana could receive an automatic hearing to consider modification of their sentences. The measure applies to people whose convictions or adjudications are for conduct that occurred prior to July 1, 2021, when a state law legalizing personal possession and home cultivation of marijuana went into effect. Also last Tuesday, the House passed on third reading a bill to enact what’s known as “Ryan’s law,” a policy change providing that patients with terminal illnesses who are registered cannabis patients can access medical marijuana at health facilities such as hospitals. The chamber approved that legislation, HB 75 from Del. Karen Keys-Gamarra (D), in a 95-1 vote. It would require healthcare facilities to establish policies “to address circumstances under which an eligible patient would be permitted to use medical cannabis.” Under the House legislation, healthcare facilities could suspend medical cannabis allowances if a federal agency such as the Department of Justice or Centers for Medicare and Medicaid Services takes enforcement action on the issue or issues a rule or notification expressly prohibiting use of medical cannabis in health facilities. The Senate passed differing legislation concerning the use of medical cannabis in health care facilities earlier this month. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, the Virginia House this month approved a bill to protect the rights of parents who use marijuana in compliance with state law. Under the proposal from Del. Nadarius Clark (D), possession of use of cannabis by a parent or guardian on its own “shall not serve as a basis to deem a child abused or neglected unless other facts establish that such possession or consumption causes or creates a risk of physical or mental injury to the child.” “A person’s legal possession or consumption of substances authorized under [the state’s marijuana law] alone shall not serve as a basis to restrict custody or visitation unless other facts establish that such possession or consumption is not in the best interest of the child,” the text of the bill, HB 942, states. Separately, the Virginia Department of Labor and Industry recently published a new outlining workplace protections for cannabis consumers. Photo courtesy of Chris Wallis // Side Pocket Images. The post Virginia Republican Lawmakers Explain Why They Voted To Legalize Marijuana Sales appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I merely imagined it usually is a perception to write could possibly help anybody ended up being experiencing difficulity looking into nevertheless We are somewhat doubtful only are permitted to placed labels along with details in below. abonnement iptv hd

FL legalization signatures zeroed out; MD & HI psychedelics votes; CT medical marijuana in hospitals bill; Study: Cannabis munchies are real Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Centers for Medicare & Medicaid Services Administrator Mehmet Oz warned “there are going to be consequences” as more Americans choose marijuana over alcohol—including problems caused by “high-dose hemp and CBD,” even as his agency is preparing to roll out a plan to cover cannabidiol through Medicare. The Florida Department of State’s Elections Division has reset the valid signature count for a marijuana legalization ballot initiative to 0 under a new law that doesn’t allow the hundreds of thousands of petitions the campaign collected for 2026 to be carried over into the 2028 cycle. The Maryland House of Delegates and Senate Finance Committee approved bills to extend the Task Force on Responsible Use of Natural Psychedelic Substances for a year and require a new report with recommendations to ensure “broad, equitable and affordable access to psychedelic substances.” The Hawaii Senate Health and Human Services Committee approved a bill to create a psychedelics task force to study and make recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. The Connecticut legislature’s Joint Committee on Public Health held a hearing on a bill to let terminally ill patients use medical cannabis in healthcare facilities such as hospitals, nursing homes and hospices. A new study confirms that marijuana really does give you the “munchies”—and reveals which types of food people desire the most after consuming cannabis. / FEDERAL Former Rep. Patrick Kennedy (D-RI) posted a video praising prohibitionist organization Smart Approaches to Marijuana. / STATES The South Dakota House of Representatives passed a bill to eliminate the Medical Marijuana Oversight Committee. The Michigan Supreme Court will hold oral arguments in two marijuana-related cases next month. Washington, D.C. regulators finalized medical cannabis advertising and signage rules. Vermont regulators sent a warning about scams targeting cannabis businesses. Missouri regulators are working to launch a media campaign warning young people about the risks of using marijuana. Colorado generated $236.4 million worth of marijuana tax revenue in 2025. California regulators sent updates about various cannabis issues. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL The German Bundestag Petitions Committee held a hearing on a petition to stop planned changes to the medical cannabis program. / SCIENCE & HEALTH A study found “improvements in subjective sleep quality and other captured [patient-reported outcome measures] in insomnia patients treated with cannabis-based medicinal products.” A review’s results “support the potential application of psilocybin for treating major depressive disorder.” / ADVOCACY, OPINION & ANALYSIS The Christian Democratic Union of Germany adopted a resolution calling for a repeal of the country’s marijuana legalization law. / BUSINESS MTL Cannabis Corp. received court approval for its acquisition by Canopy Growth Corporation. Canadian retailers sold C$503.7 million worth of legal marijuana products in December. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Dr. Oz warns about cannabis as alcohol alternative (Newsletter: February 24, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Sustain the nice do the job, When i understand several threads within this web page in addition to I'm sure that a world-wide-web blog site is usually authentic useful possesses bought communities connected with excellent facts. abonnement iptv hd

121. Microdosing for Midlife: Stability & Nervous System Change (Week 4) Week 4 of Microdosing for Midlife explores how nervous system stability shapes identity, growth, and long-term change in midlife. Episode Summary This episode is part Week 4 of Microdosing for Midlife—a 12-part audio companion to the original Substack series. In this conversation, April expands on what it actually means to feel stable while undergoing change. Midlife often brings visible transitions—shifts in hormones, identity, relationships, ambition—but underneath those external markers is something quieter: the nervous system recalibrating itself. Rather than focusing on dramatic breakthroughs, this episode examines how safety, steadiness, and subtle internal shifts create sustainable growth. Instead of chasing intensity, April reflects on how microdosing can support capacity—capacity to tolerate discomfort, to remain present in uncertainty, and to integrate insight gradually. The real work is not in peak moments. It’s in the ability to return to baseline without abandoning yourself. Key Takeaways How nervous system stability shapes long-term growth in midlife Why intensity is often mistaken for progress How subtle shifts accumulate into meaningful identity change What “capacity building” looks like beyond insight A reflection question to carry into the week ahead Timestamps [00:00] Episode opening[02:00] Framing the week’s theme[08:30] Nervous system stability vs intensity[15:00] Capacity building in midlife[22:00] Integration reflection[27:00] What to carry forward Resources Micro-Psyched 12-Week Microdosing Program Upcoming Psychedelic Salon tickets Follow April on Substack Original Microdosing for Midlife Substack post:https://aprilpride.substack.com/p/vagus-nerve-menopause-psilocybin-intuition-body-trust Hosted by April Pride @aprilpride_ Follow on IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset Get full access to SetSet with April Pride at aprilpride.substack.com/subscribeCatch the full episode here

In crossy road, you steer the character through challenges like busy streets, flowing rivers, and oncoming vehicles, striving to achieve the highest score possible.

Thanks for the nice blog. It was very useful for me. I'm happy I found this blog. Thank you for sharing with us,I too always learn something new from your post. zarif wijdan lawn

I appreciate the thoughtfulness you put into your content. https://www.edmontonfurnacecare.com/

Connecticut lawmakers are among the latest in the U.S. to take up legislation to allow medical marijuana use by certain qualifying patients at health facilities such as hospitals, nursing homes and hospices. Members of the legislature’s Joint Committee on Public Health convened to discuss the cannabis bill at a hearing on Monday, taking testimony from state agencies, medical institutions and more as they consider implementing a policy known as “Ryan’s law,” named after a young California medical cannabis patient who passed away. Under the proposal, terminally ill patients could access cannabis products that could not be smoked or vaporized at health facilities such as hospitals. That would not extend to patients receiving emergency care, however. The bill, HB 5242, also stipulates that health facilities could suspend the medical cannabis allowance if a federal agency such as the Justice Department or Centers for Medicare & Medicaid Services (CMS) initiates an enforcement action or issues guidance specifically prohibiting medical marijuana access on their premises. Erin Gorman Kirk, Connecticut’s Cannabis Ombudsman, advised the joint committee that current policy means “a registered patient facing a terminal prognosis may be forced to abandon their legally authorized regimen the moment they are admitted to a hospital or nursing home.” “Patients who cannot or will not tolerate opioids, or who have found in medical cannabis the only effective relief for their pain, nausea, or anxiety, are left without options simply because of where they receive care,” she said. “HB 5242 corrects this by requiring covered facilities to allow those with a terminal prognosis of one year or less, to use non-smokable cannabis forms including tinctures, edibles, and topicals.” “HB 5242 is important, impactful, and morally necessary. It is a n ethical, commonsense bill that protects vulnerable patients who do not want opioids, who cannot tolerate them, or who have simply found in cannabis the relief and clarity that allows them to die with dignity. Medical cannabis is backed by clinical evidence, endorsed by nurses and policy analysts who work with these patients every day, and modeled on laws that are working right now in states across the country. Connecticut should not be a state that tells a dying patient: your medicine is legal, your doctor approved it, but you cannot have it here.” The Connecticut Hospital Association (CHA), meanwhile, voiced opposition to the proposal, telling lawmakers that the bill “misapprehends several issues about the laws and regulations governing hospitals.” “HB 5242 requires Connecticut hospitals to break the law—a law that [the Department of Public Health, or DPH] itself will need to enforce as part of the [Centers for Medicare and Medicaid Services, or CMS] oversight system and the Department of Consumer Protection (DCP) would need to enforce as part of its role overseeing controlled substances laws,” it said. The Connecticut Association of Health Care Facilities and Connecticut Center for Assisted Living (CAHCF/CCAL) also submitted testimony in opposition to the reform, advising that “compliance would place providers in a very difficult and untenable situation of trying to navigate conflicting federal and state laws.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Lawmakers in multiple states are advancing similar bills meant to provide patients with access to medical marijuana in health care facilities, with legislators across the U.S. making the case this week for a policy change they say is necessary to ensure patients have a full range of treatment options at their disposal. Last week alone, Ryan’s law proposals saw action in at least four states: Colorado, Hawaii, Virginia and Washington State. Photo courtesy of Philip Steffan. The post Connecticut Lawmakers Take Up Bill To Allow Medical Marijuana Access In Hospitals appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Hawaii senators have advanced a bill to create a psychedelics task force responsible for studying and making policy recommendations on providing access to breakthrough therapies such as psilocybin and MDMA. Members of the Senate Health and Human Services Committee approved the legislation from Sen. Chris Lee (D), with amendments, in a 5-0 vote on Wednesday. The measure would create a Mental Health Emerging Therapies Task Force that’d be tasked with spending two years reviewing the current scientific literature, supporting additional clinical research and “developing policy recommendations for safe, ethical, and culturally-informed implementation” of a psychedelics therapy program. “The legislature finds that addressing the mental health crisis affecting the residents of the State, particularly among veterans, first responders, and trauma survivors, is urgent,” the bill, SB 3199, states. “Suicide continues to be a leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.” Noting that the federal Food and Drug Administration (FDA) has already designated psilocybin and MDMA as breakthrough therapies in the treatment of serious mental health conditions, which could lend to future rescheduling under the Controlled Substances Act (CSA), the Hawaii legislation says the state “must proactively prepare public health, clinical, and research systems for safe and equitable implementation.” Members of the task force would have to include representatives of the state Department of Health (DOH), the attorney general’s office, the Office of Wellness and Resilience (OWR), the University of Hawaii’s medical school and more. As drafted, DOH would have overseen the task force, but that was amended in committee to make it the responsibility of “an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education.” “Administrative placement of the task force within an entity with demonstrated expertise in primary scientific research and pharmaceutical or medical education shall not be construed to transfer, delegate, diminish, expand, or otherwise modify any regulatory, enforcement, licensing, scheduling, or rulemaking authority vested in the Department of Health, Board of Pharmacy, or any other state agency,” the bill as revised says. “All statutory authority relating to controlled substances, professional licensure, and public health regulation shall remain with the appropriate executive branch agencies as provided by law.” The proposal has been referred to the House Ways & Means Committee for further discussion. It appears that the bill would build upon prior work conducted by a separate psychedelics task force that convened for the first time in 2023, with a similar goal of exploring pathways for therapeutic access into FDA-approved breakthrough drugs like psilocybin. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, Hawaii senators recently approved a bill to legalize low-dose and low-potency marijuana, even as their counterparts in the House of Representatives say cannabis prohibition will not be ended in the state this year. The Health and Human Services Committee on Wednesday also approved a bill to allow patients to immediately access medical cannabis once their registrations are submitted, instead of having to wait until their cards are delivered as is the case under current law. A separate marijuana legalization bill that contained provisions making the reform contingent on changes to federal law or the state Constitution, SB 2421, was deferred for action. Both Senate and House panels additionally deferred action on a measure to allow for the sale of certain hemp-derived cannabinoid products. The Senate committee action comes after key House lawmakers signaled that cannabis legalization proposals would not be advancing in the 2026 session, citing a lack of sufficient support in their chamber. Image courtesy of CostaPPR. The post Hawaii Senators Approve Bill To Create Psychedelics Task Force To Study Pathways For Access To Psilocybin, MDMA And More appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A Florida campaign seeking to put marijuana legalization on the ballot is facing another complication as it continues to litigate the status of its 2026 signature drive. Under a new election law, the hundreds of thousands of signatures activists already collected for this year will not be carried over into the 2028 cycle. Gov. Ron DeSantis (R) signed a bill into law last year that makes several fundamental changes to the ballot process in a way that advocates say significantly undermines their ability to put citizen initiatives before voters, including a policy to reset the signature clock for each election cycle. Accordingly, the state Division of Elections page for the Smart & Safe Florida cannabis measure now shows 0 verified signatures for the 2028 ballot, erasing the nearly 800,000 signatures the campaign gathered to put legalization on the ballot this November. Officials said activists failed to meet the signature threshold for this upcoming election, but that matter is still being separately challenged in the state Supreme Court. “The new law means all signatures expire for the new cycle,” a Smart & Safe Florida spokesperson told Marijuana Moment on Monday, calling it “one more way they screwed over voters.” Other changes to the state election law includes new policies creating stricter formatting rules for ballot petitions, registration requirements for signature collectors, limitations on the number of ballot issues per campaign committee and more. The cannabis campaign hasn’t given up its bid for the 2026 ballot just yet, however. And so depending on the outcome of the pending litigation, it could theoretically avoid navigating the updated election rules for 2028. Smart & Safe Florida recently submitted an appeal to the state Supreme Court concerning the invalidation of about 71,000 signatures for its 2026 petition, for example. While the court agreed to close a separate case involving a legal review into the ballot measure from Smart & Safe Florida, it’s now been handed another case challenging the earlier mass signature invalidation. Back in December, advocates filed a lawsuit in the Leon County circuit court, claiming Secretary of State Cord Byrd (R) unlawfully directed county election officials to invalidate about 42,000 signatures from so-called “inactive” voters and roughly 29,000 signatures collected by out-of-state petitioners. That lawsuit came after another court upheld a previous decision to strike about 200,000 signatures that the state said were invalid because the petitions didn’t include the full text of the proposed initiative. The campaign contested the legal interpretation, but it declined to appeal the decision based on their confidence they’d collected enough signatures to make up the difference. Smart & Safe Florida has generally disputed the secretary of state’s signature count, asserting the campaign submitted over 1.4 million petitions—hundreds of thousands more than the 880,062 valid signatures required to go before voters. In a recent filing with the Supreme Court, Attorney General James Uthmeier (R) said his office was withdrawing its earlier request for a legal review in the constitutionality of the proposed cannabis initiative because the state claimed the campaign submitted an insufficient number of signed petitions. The last count, according to the secretary of state’s office, was 783,592 validated signatures. In its reply brief, Smart & Safe Florida said the secretary of state’s office made a determination that the campaign didn’t satisfy requirements for ballot placement based on a “conclusion that the Sponsor failed to meet the requisite signature threshold in light of the invalidations that the Sponsor is contesting.” Ahead of the signature turn-in, Florida’s attorney general and several business and anti-marijuana groups urged the state Supreme Court to block the cannabis initiative, calling it “fatally flawed” and unconstitutional. The Florida Chamber of Commerce, Florida Legal Foundation and Judge Frank Shepherd filed a separate joint brief stating that the parties remain “especially vigilant about the abuse of the citizen initiative process by out-of-state interests that think of Florida as just another market and the citizen initiative process as just another means of exploiting that market.” The Florida Chamber of Commerce has consistently opposed attempts to move forward with adult-use legalization, even as its own polling has shown majority support for the reform. The campaign fought several legal battles this cycle to ensure that its initiative is able to qualify for ballot placement. Last month, the state attorney general’s office opened dozens of criminal investigations and submitted subpoenas requesting records from Smart & Safe Florida and its contractors and subcontractors over alleged fraud related to the petitioning effort. Activists said in November that they’d collected more than one million signatures to put the cannabis measure on the ballot, but it’s also challenged officials at the state Supreme Court level over delays the certification process, arguing that the review of the ballot content and summary should have moving forward months ago when it reached an initial signature threshold. The state then agreed to move forward with the processing. The governor campaigned heavily against an earlier version of the legalization proposal, which received a majority of voters in 2024 but not enough to meet the 60 percent threshold required to pass a constitutional amendment. Former Attorney General Ashley Moody (R) unsuccessfully contested the prior initiative in the courts. Last March, meanwhile, two Democratic members of Congress representing Florida asked the federal government to investigate what they described as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to DeSantis. The money was used to fight against a citizen ballot initiative, vehemently opposed by the governor, that would have legalized marijuana for adults. The lawmakers’ letter followed allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing Amendment 3. The governor said last February that the newest marijuana legalization measure is in “big time trouble” with the state Supreme Court, predicting it would be blocked from going before voters this year. “There’s a lot of different perspectives on on marijuana,” DeSantis said. “It should not be in our Constitution. If you feel strongly about it, you have elections for the legislature. Go back candidates that you believe will be able to deliver what your vision is on that.” “But when you put these things in the Constitution—and I think, I mean, the way they wrote, there’s all kinds of things going on in here. I think it’s going to have big time trouble getting through the Florida Supreme Court,” he said. The latest initiative was filed with the secretary of state’s office just months after the initial version failed during the November 2024 election—despite an endorsement from President Donald Trump. Smart & Safe Florida expressed optimism that the revised version would succeed in 2026. The campaign—which in the last election cycle received tens of millions of dollars from cannabis industry stakeholders, principally the multi-state operator Trulieve—incorporated certain changes into the new version that seem responsive to criticism opponents raised during the 2024 push. For example, it now specifically states that the “smoking and vaping of marijuana in any public place is prohibited.”Another section asserts that the legislature would need to approve rules dealing with the “regulation of the time, place, and manner of the public consumption of marijuana.” In 2023, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released last February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In the background, a recent poll from a Trump-affiliated research firm found that nearly 9 in 10 Florida voters say they should have the right to decide to legalize marijuana in the state. Meanwhile, earlier this month, Florida senators approved an amended bill to increase the amount of medical marijuana a registered patient can buy and slash the fee for medical cannabis identification cards for military veterans. The vote came after the Senate Regulated Industries Committee passed separate legislation to ban smoking or vaping marijuana in public places. Rep. Alex Andrade (R) is sponsoring a similar bill to ban public cannabis smoking in the House. Here’s an overview of other pending Florida marijuana bills: A House lawmaker is sponsoring a bill to legalize recreational marijuana that also aims to break up what he calls “monopolies” in the state’s current medical cannabis program by revising the business licensing structure. Another representative’s bill would protect the parental rights of medical cannabis patients, preventing them from losing custody of their children for using their medicine in accordance with state law. A senator is sponsoring a bill to legalize home cultivation of marijuana for registered medical cannabis patients in the state. Photo courtesy of Chris Wallis // Side Pocket Images. The post Florida Officials Reset Marijuana Campaign’s Signatures To Zero For Legalization Ballot Initiative As Legal Challenges Persist appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Mehmet Oz, the head of the Centers for Medicare & Medicaid Services (CMS), says “there are going to be consequences” as more Americans choose marijuana over alcohol—including problems caused by “high-dose hemp and CBD.” As the Trump administration works to finalize a cannabis rescheduling proposal and prepares to roll out a CBD coverage plan through Medicare under Oz’s agency, the health official curiously raised concerns about non-intoxicating cannabidiol and hemp products overall. During an interview with Katie Miller—the wife of top Trump advisor Stephen Miller—Oz was asked whether shifts in consumer preferences away from alcohol and toward cannabis pose any risks. And the CMS administrator answered affirmatively. “Anything that’s strong enough to help you is strong enough to hurt you. So yes, there are going to be consequences,” he said. “We already know that some of the high-dose hemp and CBD is a problem.” The comments are especially notable given that Oz is leading an initiative tied to the marijuana rescheduling executive order President Donald Trump issued in December that’s meant to incorporate CBD coverage under federal health care programs. The health official has made multiple statements over recent years supporting the therapeutic use of marijuana and its constituents. As part of Trump’s executive order, the attorney general was separately directed to expeditiously complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA). As for hemp and CBD, those were federally legalized under the 2018 Farm Bill the president signed into law during his first term, though industry advocates have warned about cannabinoid products’ continued availability under more recent legislation Trump approved to recriminalize hemp THC. Trump himself shared a video on Truth Social last year touting the benefits of CBD, particular for seniors. Meanwhile, an industry stakeholder working with the administration on its CBD Medicare initiative said recently that CMS already finalized a rule to provide federal health insurance coverage for the cannabinoid, but the White House has not confirmed the status of the rulemaking. Oz, for his part, spoke about the initiative at the signing ceremony for the underlying executive order, crediting Trump and U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for “pushing for change” and “relentlessly” pursuing an agenda rooted in a “deep passion for research.” The plan has been to create a pilot program enabling eligible patients to access hemp-derived cannabidiol that’d be covered under federal health insurance plans, projected to launch by April, according to Oz. At the signing ceremony in December, Oz also gave kudos to Howard Kessler, founder of The Commonwealth Project, which produced the video about the benefits of cannabidiol for seniors that Trump shared. While CMS implemented an earlier final rule last April specifically stipulating that marijuana, as well as CBD that can be derived from federally legal hemp, are ineligible for coverage under its Medicare Advantage program and other services, the agency is now revising that policy. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — CMS had already announced certain changes as part of a rulemaking process that was unveiled late last year, affecting “marketing and communications, drug coverage, enrollment processes, special needs plans, and other programmatic areas” for insurance programs it oversees. One of those changes dealt with cannabidiol coverage. In recent years, Oz has encouraged audiences to be open to therapeutic cannabis and advocated for sweeping policy changes around the drug. “We ought to completely change our policy on marijuana. It absolutely works,” he said in a 2020 interview, calling cannabis “one of the most underused tools in America.” In 2024, he wrote in a syndicated health column that there’s evidence cannabinoids can curb seizures, alleviate nausea associated with cancer treatment and potentially help manage pain—especially in older people. Oz also said in 2020 that he believes that, particularly for seniors, marijuana for pain represents a “safer solution than, for example, narcotics in many cases.” The post Dr. Oz Warns Of ‘Consequences’ As People Choose Marijuana Over Alcohol, Citing Concerns About ‘High-Dose Hemp And CBD’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

La mutation des usages vers les écrans portables a imposé une révision complète de la conception des interfaces, et l'ergonomie tactile de https://julius-casino-fr.one/ représente un modèle du genre. L'ensemble de la navigation a été repensé pour s'adapter aux interactions par gestes. Les zones de balayage et les boutons d'action sont idéalement proportionnés pour éviter les erreurs de manipulation, garantissant une utilisation confortable même sur les écrans de taille réduite.

The Maryland House of Delegates has approved a bill to extend a psychedelics task force through the end of 2027 to develop updated recommendations on expanding therapeutic access to the novel drugs and potentially creating a regulatory framework for broader legalization. Meanwhile, a Senate committee advanced a companion measure with a minor amendment. Just days after moving through the House Health Committee, the full chamber passed the legislation from Del. Pam Guzzone in a 110-25 vote on Thursday. On the same day, the Senate Finance Committee approved that chamber’s version of the measure, sponsored by Sen. Brian Feldman (D), but with an amendment to add a representative of a historically black college or university to the task force. The panel had held a hearing on the psychedelics measure days earlier. Both chambers’ proposals are aimed at building upon a current law that created the Maryland Task Force on Responsible Use of Natural Psychedelic Substances. “It’s just to give them one extra year to finish out their work. So it’s just to extend it for one year—to expand it in any way,” Del. Teresa Woorman (D) said on the House floor on Thursday. “We’re not changing their mandate or anything. We’re just giving them one more year to finish out the reporting.” “They gave us a great work up in committee about all the work that they’ve done, and all of their research has been published. They have produced over 200 pages of documents,” she said.”But they could just really use the extra year to just pile up everything. There’s a lot of expertise on the panel, and it would be a shame to not let them finish out their work before we have to wrap up this task force and start over again.” That panel released an initial final report to state lawmakers last year, with recommendations for the phased implementation of a wide range of reforms to provide legal therapeutic access to substances such as psilocybin. Members of the task force have already advised that it was ultimately recommending a “multi-pathway framework for safe, broad, and equitable access to natural psychedelic substances, with an initial focus on psilocybin.” The psychedelics task force was formed following Gov. Wes Moore’s (D) signing of a pair of bills into law in 2024. The 17-person body, overseen by the Maryland Cannabis Administration (MCA), was charged with studying how to ensure “broad, equitable and affordable access to psychedelic substances” in the state. SB 336 and HB 427 would continue that work, maintaining the panel through December 31, 2027. In the interim, the task force would be required to submit an updated report to legislators with additional findings and recommendations by October 31 of this year. Beyond the extended timeline for the task force to study and develop the report, the current law would not change under the legislation. The multi-step regulatory framework that members recommended last year “involves phased implementation of complementary elements from medical/therapeutic use and supervised adult use, to deprioritization, and to commercial sales,” the report said. “This model broadly and inclusively serves the needs of Maryland’s diverse population while enabling unified safety standards, accountability, and viable economic pathways for small businesses.” The first phase of the plan would be to create an advisory board to establish safety parameters, data monitoring, practice guidelines, licensing protections, public education campaigns, training for facilitators, law enforcement and testing facilities, as well as “immediate restorative justice measures,” the report states. Under phase two, the state would implement “deprioritization measures” to mitigate the harms of criminalization, provide for supervised medical and adult-use consumption facilities, allow personal cultivation for “permitted individuals” and promote research processes. Finally, phase three would be contingent on the “demonstrated safety outcomes and provider confidence” based on the prior steps. Should those factors be satisfied, the last phase would lead to a commercial sales program for adults “who maintain an active license to use natural psychedelic substances,” coupled with an evaluation of the state’s “readiness for expanding to additional natural psychedelic substances.” “Safety and oversight measures ensure responsible and gradual expansion of access while maintaining capacity to identify and respond to emerging issues swiftly,” the report said. “This approach plans for long-term learning and improvement: starting small, utilizing built-in evaluation and accountability mechanisms from the outset, gathering real-world data, and committing to an iterative approach to policymaking.” Notably, the task force said it did not support “delaying state action pending future federal [Food and Drug Administration] approval.” “The Task Force recognizes that implementing such a comprehensive framework requires careful sequencing and coordination, with particular attention to scope of practice issues that may significantly affect the viability and safety of different pathways. However, the order of implementation must carefully consider professional regulatory frameworks and safety concerns raised by medical organizations and health care providers. The Task Force’s recommendation for simultaneous implementation of multiple pathways does not mean that all components must activate on the exact same day, but rather that Maryland should avoid the sequential approach seen in other jurisdictions where implementing one pathway causes others to ‘languish,’and/or bolster black and gray markets.” Rather, the task force said, the multi-phase approach to psychedelics reform “establishes foundational systems that support all pathways equally, followed by a coordinated launch of medical, supervised adult use, and deprioritization pathways, with commercial sales following once product safety systems are operational.” Members also said that the model envisioned could be used by other states to develop their own laws that “adapt to their own circumstances and values.”At this point, the task force is only looking at psilocybin, mescaline and DMT. While the legislature empowered members to investigate potential regulations for other psychedelic substances, they decided to take a more conservative approach in their initial work. As originally introduced, the House version of the task force legislation contained more prescriptive requirements to explore and issue recommendations on aspects of psychedelics policy such as “systems to support statewide online sales of natural psychedelic substances with home delivery” and “testing and packaging requirements for products containing natural psychedelic substances with clear and accurate labeling of potency.” That language was ultimately removed, however. The task force legislation advanced about two years after a different law took effect creating a state fund to provide “cost-free” access to psychedelics like psilocybin, MDMA and ketamine for military veterans suffering from PTSD and traumatic brain injury. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, earlier this month, Maryland lawmakers took up a bill to protect the gun rights of medical marijuana patients in the state. Members of the House Judiciary Committee discussed the legislation from Del. Robin Grammer (R), who has sponsored multiple versions of the cannabis and gun rights measure over recent sessions, but they have not yet advanced to enactment. Meanwhile, a Republican congressional lawmaker representing Maryland who has built a reputation as one of the staunchest opponents of marijuana reform on Capitol Hill—and whose record includes ensuring that Washington, D.C. officials are blocked from legalizing recreational cannabis sales—may be at risk of being unseated in November due to redistricting in his state. Photo elements courtesy of carlosemmaskype and Apollo. The post Maryland Lawmakers Approve Bills To Extend Psychedelics Task Force Through 2027 appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Getting the “munchies” after using marijuana isn’t just in your head. It’s a real biological phenomenon that could hold important, real-world implications for people suffering from conditions associated with appetite loss, according to a new study that also identified some of the most commonly desired food items while high. Researchers at Washington State University (WSU) and the University of Calgary sought out to investigate the well-known cannabis experience, which is often comically portrayed in media as a hunger-inducing side effect that’s coupled with copious consumption of Doritos and other unhealthful snack foods. While that might be how some people manage the munchies, the appetite stimulation associated with cannabis has the potential to meaningfully help people with serious health conditions, the researchers said in the study, which was recently published in the Proceedings of the National Academy of Sciences (PNAS). The human clinical trial involved 82 volunteers aged 21 to 62. Participants were randomly assigned to vape either 20 or 40 milligrams of cannabis, or a placebo for the control group, and were assessed to determine what kind of factors might impact the appetite effect. The study also involved similar assessments using a rat model. “Cannabis acutely and robustly increases energy intake, food motivation, and reward value, irrespective of food type, satiety, food aversion, and gender/sex.” “There are a lot of different diseases, conditions and disorders associated with wasting syndromes and lack of appetite, and this study really supports the idea that cannabis can be used medicinally to increase appetite in people who have conditions like HIV, AIDS, or who are on chemotherapy,” Carrie Cuttler, a psychology professor at WSU, said in a press release. Interestingly, the study found that people didn’t universally gravitate toward one type of food option over another. Some participants were inclined to eat carbohydrate-heavy foods, others preferred proteins and some fell closer into the stereotype by choosing fatty snack foods. But there were some common, if unexpected, themes. “Beef jerky was one of the No. 1 things intoxicated people gravitated toward, which I don’t understand. Honestly, I would have thought chocolate, chips, Rice Krispies treats—things like that,” Cuttler said, adding that water was among the most desired items. Ryan McLaughlin, a WSU veterinary science professor, said that the “human study found irrespective of body mass index, time of last food consumption, sex or how much cannabis was consumed, human participants who used cannabis during the trial ate significantly more food,.” The rat-based trial similarly demonstrated that cannabis commonly triggered an appetite response in the animals, which pulled levers to obtain food at a much higher rate compared to the control group. “The sober animals are kind of like, ‘I’m full. Why do I care?’ They don’t put in any effort at all. They barely work in any capacity to get access to food,” The University of Calgary’s Matthew Hill said. “But you get them stoned again, and even though they’re now full and they’ve eaten, they go right back as if they’re starving.” “The same thing we saw in the humans we saw in the rats. We kind of thought it would make them want to eat carb-rich foods, but that didn’t seem to be the case. It just seemed to be any food,” he said. The findings reinforce what’s been established in earlier research into the endocannabinoid system. THC stimulates the hypothalamus and “hijacks that entire system,” McLaughlin said. “So even though you’re not necessarily hungry, THC can stimulate cannabinoid receptors in the brain and make you feel hungry.” “That’s what really gives us the opportunity to look at whether this is something brain-mediated or gut-mediated, and this generally shows ‘the munchies’ are mediated by the brain,” he said. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — This is far from the only study to look at the relationship between marijuana and appetite. For example, in 2024, WSU researchers separately published a federally funded study that identified exactly what happens in the brain after using marijuana that causes the munchies. The research, published in Scientific Reports, revealed how cannabis activates a specific cluster of neurons in the hypothalamus region of the brain that stimulates appetite. A 2019 study separately found that sales of commonly munched on products like ice cream, cookies and chips tend to go up after states legalize cannabis. Despite that, a 2022 study determined that adult-use legalization is actually associated with decreased levels of obesity despite the fact that cannabis is well-known appetite stimulator. In 2024, meanwhile, a meta-analysis also found that people who use marijuana are about half as likely to develop type 2 diabetes. The post Scientists Reveal What Types Of Food The Marijuana ‘Munchies’ Make You Crave The Most appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

it's truly wonderful weblog. it's realy educational along with a this type of great work. i really like this particular. สล็อตเว็บตรง